Sharing Safety And Efficacy Data With Patients With Metastatic Urothelial Carcinoma

Sharing Safety and Efficacy Data with Patients with Metastatic Urothelial Carcinoma (mUC)

The evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma

Touch Medical Media

Optimal treatment strategies for patients with metastatic urothelial carcinoma

JAVELIN: safety and efficacy 2-year follow up

Enfortumab vedotin for urothelial cancer in the real-world setting

FORT-2: rogaratinib and atezolizumab in urothelial cancer

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malign...

Updated Efficacy Results for Avelumab in Metastatic Urothelial Carcinoma

Targeted Oncology

Dr. Rafii on Durvaluamb in Patients With Urothelial Bladder Cancer

Treatment Considerations for Patients With Metastatic Urothelial Carcinoma

Targeted Oncology

Erdafitinib demonstrates efficacy in intermediate-risk NMIBC with FGFR alterations

THOR-2 Cohort 3 interim analysis: erdafitinib in intermediate-risk NMIBC with FGFR3/2 alterations

Safety and efficacy of the erdafitinib intravesical delivery system: Phase 1: first-in-human study

European Association of Urology

State of the Art lecture - Developments in metastatic urothelial cancer

European Association of Urology

Providing the Best Care for Patients with Metastatic Urothelial Carcinoma (mUC)

Dr. Zhang on the IMvigor130 Trial in Metastatic Urothelial Cancer

Targeted Therapy for the Treatment of Advanced Metastatic Urothelial Cancer YouTube

Grand Rounds in Urology

How effective are ADCs in treating metastatic urothelial cancer?

THOR: erdafitinib in metastatic urothelial cancer with FGFR alterations

Safety Data from JAVELIN Bladder 100